Xencor, Inc. (XNCR) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Etzer Darout
Barclays Bank PLC, Research Division

Hello again, everyone. My name is Etzer Darout, one of the senior biotech analysts at Barclays. My pleasure to welcome Xencor to our fireside chat. With us today, we have Bassil Dahiyat, President and Chief Executive Officer; Dane Leone, Executive Vice President of Strategy. And so thank you guys for joining us today. Maybe, Bassil, just to kick us off, just give us a broad overview of Xencor and some of the milestones that you would like to hit in 2026.

Bassil Dahiyat
Co-Founder, CEO, President & Director

So Xencor is a company that was founded around really world-leading protein engineering technology. We’ve established ourselves over the last couple of decades as people who can create antibodies that can truly have best-in-class properties. There’s multiple marketed products we’ve built. Our technology is used widely around pharma to have created a broad pipeline in oncology, autoimmune disease and other areas.

Right now, we’re focused on building our own internal proprietary pipeline of drugs that we’ve built with these techniques, and we focused in solid tumors, particularly T-cell engagers for solid tumors, a class that’s really emerging that we’ve managed to put ourselves into the forefront of and then best-in-class bispecific and long-acting antibodies in autoimmune disease. Critical for us in the next 12 to 18 months are define fully the dosing regimens and efficacy safety profiles for our 2 lead solid tumor T cell engager CD3 bispecific antibodies, XmAb819 and 541 that we expect to have recommended Phase III doses and pivotal plans by